Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8037756 | 1.00 | MDM4 (0.49) | MDM4TP53CASP3KMT2APIN1 | |
| SCHEMBL28341996 | 1.00 | MDM4 (0.49) | MDM4TP53CASP3KMT2APIN1 | |
| SCHEMBL30785203 | 1.00 | MDM4 (0.49) | MDM4TP53CASP3KMT2APIN1 | |
| SCHEMBL3439365 | 0.93 | CASP3 (0.48) | MDM4TP53CASP3KMT2APIN1 | |
| SCHEMBL5500174 | 0.89 | MDM4 (0.44) | MDM4TP53CASP3KMT2APIN1 | |
| SCHEMBL119402 | 0.89 | CASP3 (0.50) | MDM4TP53CASP3KMT2APIN1 | |
| SCHEMBL1738651 | 0.89 | CASP3 (0.50) | MDM4TP53CASP3KMT2APIN1 | |
| SCHEMBL2366569 | 0.89 | CASP3 (0.50) | MDM4TP53CASP3KMT2APIN1 | |
| SCHEMBL2366563 | 0.89 | CASP3 (0.50) | MDM4TP53CASP3KMT2APIN1 | |
| SCHEMBL31575313 | 0.89 | CASP3 (0.50) | MDM4TP53CASP3KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989313-B | P-tau181 epitope peptide and application thereof in Alzheimer disease detection | 福建亿彤生物科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-114989313-A | P-tau181 epitope peptide and application thereof in Alzheimer disease detection | 亿彤科技发展(福建)有限公司 | 2022-09-02 | — | — | CN | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PEPTIDREAM INC. (JP) | 2025-11-27 | — | — | US | disclosed |
| US-12441760-B2 | Amino diacids containing peptide modifiers | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-10-14 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20250163120-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-05-22 | — | — | US | disclosed |
| US-20110086846-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20110086846-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-7879873-B2 | Azaindazole compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20100197607-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2010-08-05 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-20090275520-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2009-11-05 | — | — | US | disclosed |
| US-7524926-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20060205664-A1 | Mucin hypersecretion inhibitors and methods of use | WILLIAMS, MASON L. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086846-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | MDM4 4809/4885TP53 4558/4885CASP3 1842/4885 |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | MDM4 4809/4885TP53 4558/4885CASP3 1842/4885 |
| US-12441760-B2 | Amino diacids containing peptide modifiers | PTMS, PEPD, NGLY1 | MDM4 930/4885TP53 1067/4885CASP3 1940/4885 |
| US-20250163120-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | IAPP, INSR, INSRR | MDM4 4329/4885TP53 3076/4885CASP3 4468/4885 |
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | MDM4 4142/4885TP53 2781/4885CASP3 1091/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | MDM4 51/4885TP53 1041/4885CASP3 4010/4885 |
| US-20250262312-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MDM4 1741/4885TP53 692/4885CASP3 511/4885 |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | BMP4, BMP1, BMPR2 | MDM4 3599/4885TP53 3024/4885CASP3 3988/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | MDM4 3559/4885TP53 2654/4885CASP3 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.